MBX Biosciences raises ~$87.1M in ATM offering; 2.25M shares sold at $38.76 VWAP

MBX Biosciences, Inc.

Closed sale of 2,250,986 shares at a volume-weighted average price of $38.76 for gross proceeds of approximately $87.1 million on February 4, 2026.
Shares sold under Open Market Sale Agreement with Jefferies dated November 6, 2025, and shelf registration statement effective December 8, 2025.
Net proceeds to fund clinical-stage programs, discovery R&D, working capital, and potential in-licensing or acquisitions.
Following this sale, up to $62.9 million in additional common stock remains available for future ATM sales through Jefferies.
Company retains flexibility to use proceeds for general corporate purposes and complementary business investments.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.